Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Boehringer Ingelheim

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,198,533

« Back to Dashboard

Summary for Patent: 5,198,533

Title: LHRH antagonists
Abstract:The present invention deals with LHRH antagonists which possess improved water solubility and while having the high antagonist potency of the basic peptides, are free of the edematogenic effects. These compounds are highly potent in inhibiting the release of gonadotropins from the pituitary gland in mammals, including humans. The compounds of this invention are represented by the formula wherein X is an acyl group derived from straight or branched chain aliphatic or alicyclic carboxylic acids having from 1 to 7 carbon atoms, or H.sub.2 N--CO, R.sup.1 is D-- or L--Pro, D-- or L--.DELTA..sup.3 --Pro, D--Phe, D--Phe(4--H1), D--Ser, D--Thr, D--Ala, D--Nal(1) or D--Nal (2), R.sup.2 is D--Phe or D--Phe(4--C1) R.sup.3 is D--Trp, D--Phe, D--Pal(3), D--Nal(1) or D--Nal(2), R.sup.6 is D--Cit, D--Hci, D--Cit(Q) or D--Hci(Q) and R.sup.10 is Gly or D--Ala where Q is lower alkyl of 1-3 carbon atoms and H1 is fluoro, chloro or bromo, and the pharmaceutically acceptable acid addition salts thereof and methods of use pertaining to these compounds.
Inventor(s): Schally; Andrew V. (Metarie, LA), Bajusz; Sandor (New Orleans, LA)
Assignee: The Administrators of the Tulane Educational Fund (New Orleans, LA)
Application Number:07/197,153
Patent Claim Types:
see list of patent claims

No matches for this query

International Patent Family for Patent: 5,198,533

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria90362► Subscribe
Brazil1100478► Subscribe
Canada1339623► Subscribe
Germany19975052► Subscribe
Germany3823590► Subscribe
Germany3881592► Subscribe
Denmark173375► Subscribe
Denmark395688► Subscribe
European Patent Office0299402► SubscribeC990029Netherlands► Subscribe
European Patent Office0299402► Subscribe099C0031Belgium► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cantor Fitzgerald
Johnson and Johnson
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: